Compare VFS & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFS | KYMR |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Vietnam | United States |
| Employees | 17823 | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.8B |
| IPO Year | N/A | 2020 |
| Metric | VFS | KYMR |
|---|---|---|
| Price | $4.29 | $84.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 26 |
| Target Price | $5.83 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 926.8K | 440.9K |
| Earning Date | 06-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $70.58 | $10.61 |
| Revenue Next Year | N/A | $8.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.78 | $28.06 |
| 52 Week High | $5.29 | $103.00 |
| Indicator | VFS | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 49.62 |
| Support Level | $3.16 | $77.71 |
| Resistance Level | $4.88 | $90.15 |
| Average True Range (ATR) | 0.25 | 3.86 |
| MACD | -0.05 | -0.30 |
| Stochastic Oscillator | 20.62 | 52.87 |
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.